Kabous, Laila

Profilbild
E-Mail-Adresse
Geburtsdatum
Projekt
Organisationseinheiten
Berufsbeschreibung
Nachname
Kabous
Vorname
Laila
Name
Kabous, Laila

Filter

2020 - 20222
Filter zurücksetzen

Einstellungen

Anfangsdatum: 2020 × Dateien dazu vorhanden?: Nein ×

Suchergebnisse

Gerade angezeigt 1 - 2 von 2
  • Vorschaubild nicht verfügbar
    Publikation
    Linking effectuation logic with business model innovation in the context of Swiss startups
    (2022) Kabous, Laila; Hinz, Andreas; Philippi, Stefan
    Effectuation and business model innovation (BMI) are research topics that are frequently discussed in the literature. While effectuation describes the effectual behaviour for founding a start-up with an emphasis on using currently available means, BMI is considered a way of creating a business model with long-term competitive advantages. Both approaches are valuable for start-ups pursuing growth in an uncertain environment. This work-in-progress paper presents insights from the reviewed extant literature. Further research will investigate effectuation and its enabling impact in designing innovative business models in the context of Swiss start-ups.
    06 - Präsentation
  • Vorschaubild nicht verfügbar
    Publikation
    Case Study "Perseo Pharma"
    (edition gesowip, 2020) Kabous, Laila; Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, Marc [in: Start-ups. Aktuelle Case Studies für den Unterricht]
    Founded in 2019, Perseo Pharma is a preclinical-stage biotech company with a unique asset for the development of enzyme therapies. Perseo Pharma possesses an innovative and proprietary enzyme shielding technology. Founded as independent spin-off of INOFEA AG, the company focuses on therapeutic enzymes for the treatment of cancer and rare genetic diseases. Over the past three decades, 30 therapeutic enzymes have been approved by EMA and FDA generating yearly 40bn. Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). This offers biotech companies different opportunities and application fields for further development of enzyme therapeutics. The goal of this research is to analyze the case based on the 7-key model and provide recommendations on the financing opportunities available for Perseo pharma.
    04A - Beitrag Sammelband